$ACUR
ACURA PHARMACEUTICALS, INC

2015 Form 10-K Financial Statement

#000114420416085018 Filed on February 29, 2016

View on sec.gov

Income Statement

Concept 2015 2014 Q4 2014 Q3
Revenue $8.587M $529.0K $145.0K
YoY Change 1043.41% 1411.43% 74.7%
Cost Of Revenue $656.0K $40.00K $110.0K
YoY Change 198.18% 0.0% 37.5%
Gross Profit $7.931M $490.0K $40.00K
YoY Change 1393.6% 300.0%
Gross Profit Margin 92.36% 92.63% 27.59%
Selling, General & Admin $8.994M $2.040M $1.728M
YoY Change 13.27% -26.88% -10.97%
% of Gross Profit 113.4% 416.33% 4320.0%
Research & Development $2.608M $910.0K $955.0K
YoY Change -43.08% 13.75% -25.91%
% of Gross Profit 32.88% 185.71% 2387.5%
Depreciation & Amortization $100.0K $190.0K $30.00K
YoY Change 0.0% 533.33% 0.0%
% of Gross Profit 1.26% 38.78% 75.0%
Operating Expenses $11.60M $2.984M $2.791M
YoY Change -7.35% -15.13% -15.63%
Operating Profit -$4.001M -$2.455M -$2.646M
YoY Change -67.2% -29.47% -17.95%
Interest Expense $1.157M -$240.0K $304.0K
YoY Change -4.54% -500.0%
% of Operating Profit
Other Income/Expense, Net -$988.0K $0.00 -$258.0K
YoY Change -2.18% -837.14%
Pretax Income -$4.989M -$2.700M -$2.904M
YoY Change -62.23% -21.05% -8.97%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$4.989M -$2.696M -$2.904M
YoY Change -62.23% -21.1% -8.97%
Net Earnings / Revenue -58.1% -509.64% -2002.76%
Basic Earnings Per Share -$0.46 -$0.30 -$0.30
Diluted Earnings Per Share -$0.46 -$0.30 -$0.30
COMMON SHARES
Basic Shares Outstanding 10.80M shares 48.85M shares 48.92K shares
Diluted Shares Outstanding 10.80M shares 48.92K shares

Balance Sheet

Concept 2015 2014 Q4 2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.84M $12.10M $14.56M
YoY Change -10.41% -53.61% -25.05%
Cash & Equivalents $0.00 $774.0K $1.250M
Short-Term Investments $10.84M $11.32M $13.31M
Other Short-Term Assets $2.902M $690.0K $950.0K
YoY Change 516.14% -15.85% 10.47%
Inventory $276.0K $304.0K $403.0K
Prepaid Expenses
Receivables $78.00K $80.00K $130.0K
Other Receivables $42.00K $60.00K $90.00K
Total Short-Term Assets $14.14M $13.23M $16.14M
YoY Change 6.83% -51.8% -22.28%
LONG-TERM ASSETS
Property, Plant & Equipment $1.013M $957.0K $960.0K
YoY Change 5.85% 1.7% -1.23%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $175.0K $0.00 $180.0K
YoY Change -100.0% 800.0%
Total Long-Term Assets $2.826M $2.802M $3.140M
YoY Change 0.86% 138.06% 215.26%
TOTAL ASSETS
Total Short-Term Assets $14.14M $13.23M $16.14M
Total Long-Term Assets $2.826M $2.802M $3.140M
Total Assets $16.96M $16.03M $19.28M
YoY Change 5.79% -44.0% -11.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $110.0K $217.0K $116.0K
YoY Change -49.31% -20.8% -54.15%
Accrued Expenses $564.0K $568.0K $1.488M
YoY Change -11.6% 4.99% 92.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.320M $1.758M $1.160M
YoY Change 31.97%
Total Short-Term Liabilities $3.244M $2.992M $3.032M
YoY Change 8.42% 170.28% 172.91%
LONG-TERM LIABILITIES
Long-Term Debt $5.430M $7.799M $8.530M
YoY Change -30.38% -18.76%
Other Long-Term Liabilities $387.0K $190.0K $140.0K
YoY Change 103.68% 1300.0%
Total Long-Term Liabilities $5.817M $7.799M $8.670M
YoY Change -27.19% -18.76% 86600.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.244M $2.992M $3.032M
Total Long-Term Liabilities $5.817M $7.799M $8.670M
Total Liabilities $9.061M $10.98M $11.70M
YoY Change -17.48% 2.56% 948.39%
SHAREHOLDERS EQUITY
Retained Earnings -$362.3M
YoY Change 3.78%
Common Stock $367.4M
YoY Change 0.1%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.900M $5.052M $7.580M
YoY Change
Total Liabilities & Shareholders Equity $16.96M $16.03M $19.28M
YoY Change 5.79% -44.0% -11.41%

Cashflow Statement

Concept 2015 2014 Q4 2014 Q3
OPERATING ACTIVITIES
Net Income -$4.989M -$2.696M -$2.904M
YoY Change -62.23% -21.1% -8.97%
Depreciation, Depletion And Amortization $100.0K $190.0K $30.00K
YoY Change 0.0% 533.33% 0.0%
Cash From Operating Activities -$3.688M -$2.350M -$2.640M
YoY Change -66.61% -25.63% -15.38%
INVESTING ACTIVITIES
Capital Expenditures $214.0K -$30.00K -$60.00K
YoY Change 58.52%
Acquisitions
YoY Change
Other Investing Activities $322.0K $1.910M $400.0K
YoY Change -84.9% -39.94% -81.04%
Cash From Investing Activities $108.0K $1.880M $350.0K
YoY Change -5500.0% -40.88% -83.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.291M 0.000 0.000
YoY Change -1117.5% -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -3.688M -2.350M -2.640M
Cash From Investing Activities 108.0K 1.880M 350.0K
Cash From Financing Activities 5.291M 0.000 0.000
Net Change In Cash 1.711M -470.0K -2.290M
YoY Change -114.79% -104.8% -216.84%
FREE CASH FLOW
Cash From Operating Activities -$3.688M -$2.350M -$2.640M
Capital Expenditures $214.0K -$30.00K -$60.00K
Free Cash Flow -$3.902M -$2.320M -$2.580M
YoY Change -65.1% -26.58% -17.31%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10000000 USD
CY2015Q1 acur Debt Instrument Cash Maintenance
DebtInstrumentCashMaintenance
2500000 USD
CY2015Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
5000000 USD
CY2015Q4 us-gaap Debt Instrument Fee Amount
DebtInstrumentFeeAmount
50000 USD
CY2015 acur Debt Consulting Placement Fee
DebtConsultingPlacementFee
100000 USD
CY2015 us-gaap Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
231000 USD
CY2015Q4 us-gaap Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
0.1016 pure
CY2015 us-gaap Debt Instrument Periodic Payment Principal
DebtInstrumentPeriodicPaymentPrincipal
1960000 USD
CY2015 acur Debt Instrument Classification Amount
DebtInstrumentClassificationAmount
0 USD
CY2015 acur Interest Expense Debt Discount
InterestExpenseDebtDiscount
121000 USD
CY2014 acur Interest Expense Debt Discount
InterestExpenseDebtDiscount
119000 USD
CY2015 us-gaap Debt Issuance Costs
DebtIssuanceCosts
65000 USD
CY2014 us-gaap Debt Issuance Costs
DebtIssuanceCosts
69000 USD
CY2013Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
13000000 USD
CY2015Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.52
CY2015 dei Document Type
DocumentType
10-K
CY2015Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
8040000 USD
CY2015 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
121000 USD
CY2014Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
281000 USD
CY2015Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
193000 USD
CY2014Q4 acur Debt Instrument Issuance Costs
DebtInstrumentIssuanceCosts
-162000 USD
CY2015 acur Amortization Expense Of Debt Instrument Issuance Costs
AmortizationExpenseOfDebtInstrumentIssuanceCosts
65000 USD
CY2015 dei Amendment Flag
AmendmentFlag
false
CY2015Q4 acur Debt Instrument Issuance Costs
DebtInstrumentIssuanceCosts
-97000 USD
CY2015Q4 us-gaap Long Term Debt
LongTermDebt
7750000 USD
CY2014 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
0 USD
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
69000 USD
CY2014 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-118000 USD
CY2015 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
CY2014 us-gaap Income Taxes Paid
IncomeTaxesPaid
14000 USD
CY2015 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
19000 USD
CY2014 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
21000 USD
CY2016Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
11833801 shares
CY2015 us-gaap Costs And Expenses
CostsAndExpenses
12588000 USD
CY2014 us-gaap Costs And Expenses
CostsAndExpenses
12950000 USD
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3000 USD
CY2015 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
3000 USD
CY2014 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
4000 USD
CY2015 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-19000 USD
CY2015 dei Document Period End Date
DocumentPeriodEndDate
2015-12-31
CY2015 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2015 dei Entity Registrant Name
EntityRegistrantName
ACURA PHARMACEUTICALS, INC
CY2015 dei Entity Central Index Key
EntityCentralIndexKey
0000786947
CY2015 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2015 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2015 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2015 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2015Q2 dei Entity Public Float
EntityPublicFloat
27000000 USD
CY2015 dei Trading Symbol
TradingSymbol
ACUR
CY2014 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1258000 shares
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
971000 shares
CY2015Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
91000 USD
CY2014Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
5000 USD
CY2015Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
362000 USD
CY2014Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
155000 USD
CY2015Q4 acur Debt Instrument Issuance Cost
DebtInstrumentIssuanceCost
97000 USD
CY2014Q4 acur Debt Instrument Issuance Cost
DebtInstrumentIssuanceCost
162000 USD
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11801000 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11801000 shares
CY2015 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Reclassifications</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Certain reclassifications have been made to the prior years' amounts to conform to the current year's presentation.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015 us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt 0.2in" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Management Estimates</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Management is required to make certain estimates and assumptions in order to prepare consolidated financial statements in conformity with GAAP. Such estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Management periodically evaluates estimates used in the preparation of the consolidated financial statements for continued reasonableness. Appropriate adjustments, if any, to the estimates used are made prospectively based on such periodic evaluations.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt 0.2in" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Concentration of Credit Risk</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> &#160;</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; TEXT-INDENT: 0.2in; MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Credit Risk</font></i></strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">: Financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash and cash equivalents, marketable securities and accounts receivable. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. However, management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. Additionally, the Company&#8217;s excess cash is invested in accordance with the investment policy approved by our Board of Directors that seeks a combination of both liquidity and safety of principal using diversification of investments, through investments such as investment grade corporate debt securities with varying maturities. To date, the Company has not experienced any material realized losses on its cash, cash equivalents, and marketable securities.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; TEXT-INDENT: 0.2in; MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> &#160;</font></i></strong> <strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; TEXT-INDENT: 0.2in; MARGIN: 0in 0in 0pt" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.2in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><i><strong><i>Customers:</i></strong> We launched our first Impede Technology product, Nexafed&#174;, in the United States in December 2012 and our Nexafed Sinus Pressure + Pain product in the United States in February 2015. Our accounts receivable arise from our sales of our Nexafed product line and represent amounts due from wholesalers in the health care and pharmaceuticals industries and from chain drug stores. The Company has performed a credit evaluation of its customers and may maintain an allowance for potentially uncollectable accounts. We have not experienced any losses on uncollectable accounts in 2015 or 2014.</i></strong></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; TEXT-INDENT: 0.2in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; TEXT-INDENT: 0.2in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Sales to certain of our customers during 2015 and 2014 accounting for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% or more of our annual product sales, whether the product shipment was recognized immediately as a sales or as a deferred sale, are presented below. Sales to customers designated with an &#8220; * &#8221; accounted for less than <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% of our annual product sales.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; TEXT-INDENT: 0.2in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">Customer</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">Rite Aid Corporation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">54</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">28</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">Cardinal Health, Inc.</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">14</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">24</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">AmerisourceBergen Corporation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">*</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">13</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">McKesson Corporation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">*</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">13</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">Kroger Foods</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">*</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">11</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> </table> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; TEXT-INDENT: 0.2in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; TEXT-INDENT: 0.2in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Accounts receivable from certain of our customers at December 31, 2015 and 2014 accounting for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% or more of our gross accounts receivable are presented below. Accounts receivable from customers designated with an &#8220; ** &#8221; accounted for less than <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% of our gross accounts receivable.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; TEXT-INDENT: 0.2in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">Customer</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">Rite Aid Corporation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">68</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">83</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">McKesson Corporation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">11</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">**</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div style="CLEAR:both;CLEAR: both">Kroger Foods</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">**</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div style="CLEAR:both;CLEAR: both">13</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q4 acur Accrued Other Professional Fees Current
AccruedOtherProfessionalFeesCurrent
92000 USD
CY2014Q4 acur Accrued Other Professional Fees Current
AccruedOtherProfessionalFeesCurrent
83000 USD
CY2015Q4 acur Marketing Advertising And Promotion
MarketingAdvertisingAndPromotion
115000 USD
CY2014Q4 acur Marketing Advertising And Promotion
MarketingAdvertisingAndPromotion
0 USD
CY2014 us-gaap Depreciation
Depreciation
100000 USD
CY2013Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
250000 USD
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
637000 USD
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
916000 USD
CY2015 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
10777000 shares
CY2014 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
9770000 shares
CY2015 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
19000 shares
CY2014 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
9000 shares
CY2015 acur Incremental Common Shares Attributable To Conversion Of Common Stock
IncrementalCommonSharesAttributableToConversionOfCommonStock
10777000 shares
CY2014 acur Incremental Common Shares Attributable To Conversion Of Common Stock
IncrementalCommonSharesAttributableToConversionOfCommonStock
9770000 shares
CY2015 acur Incremental Common Shares Attributable To Restricted Stock
IncrementalCommonSharesAttributableToRestrictedStock
19000 shares
CY2014 acur Incremental Common Shares Attributable To Restricted Stock
IncrementalCommonSharesAttributableToRestrictedStock
9000 shares
CY2015 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2014 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2015 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9770000 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9770000 shares
CY2015Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
60000 shares
CY2015 acur Additions To Debt Instrument Unamortized Discount
AdditionsToDebtInstrumentUnamortizedDiscount
33000 USD
CY2015 acur Inventory Reserve Expense Raw And Packagings
InventoryReserveExpenseRawAndPackagings
260000 USD
CY2014 acur Inventory Reserve Expense Raw And Packagings
InventoryReserveExpenseRawAndPackagings
0 USD
CY2015 acur Inventory Reserve Expense Finished Goods
InventoryReserveExpenseFinishedGoods
70000 USD
CY2014 acur Inventory Reserve Expense Finished Goods
InventoryReserveExpenseFinishedGoods
201000 USD
CY2015 acur Inventory Valuation Written Off Raw And Package
InventoryValuationWrittenOffRawAndPackage
-260000 USD
CY2014 acur Inventory Valuation Written Off Raw And Package
InventoryValuationWrittenOffRawAndPackage
0 USD
CY2015 acur Inventory Valuation Written Off Finished Goods
InventoryValuationWrittenOffFinishedGoods
0 USD
CY2014 acur Inventory Valuation Written Off Finished Goods
InventoryValuationWrittenOffFinishedGoods
-451000 USD
CY2015 acur Inventory Reserve Expense
InventoryReserveExpense
330000 USD
CY2014 acur Inventory Reserve Expense
InventoryReserveExpense
451000 USD
CY2015 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 USD
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
17923000 USD
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
890000 USD
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
606000 USD
CY2014 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1000 USD
CY2014 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
0 USD
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
8000 USD
CY2015 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
33000 USD
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
56622000 USD
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
55995000 USD
CY2015Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2014Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2015 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
52800000 USD
CY2015Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
155200000 USD
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34 pure
CY2015 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
2000000 USD
CY2015 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
600000 USD
CY2014 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2400000 USD
CY2015Q1 us-gaap Revenues
Revenues
5357000 USD
CY2015Q3 us-gaap Revenues
Revenues
210000 USD
CY2015Q4 us-gaap Revenues
Revenues
2679000 USD
CY2015Q2 us-gaap Revenues
Revenues
341000 USD
CY2015Q1 us-gaap Costs And Expenses
CostsAndExpenses
3845000 USD
CY2015Q2 us-gaap Costs And Expenses
CostsAndExpenses
2739000 USD
CY2015Q3 us-gaap Costs And Expenses
CostsAndExpenses
2615000 USD
CY2015Q4 us-gaap Costs And Expenses
CostsAndExpenses
3389000 USD
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
1512000 USD
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2398000 USD
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2405000 USD
CY2015Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-710000 USD
CY2015Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
CY2015Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2015Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2015Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
CY2015Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.13
CY2015Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2015Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
CY2015Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
1239000 USD
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-2663000 USD
CY2015 acur Issuance Of Common Stock Value Under Market Offerings
IssuanceOfCommonStockValueUnderMarketOfferings
217000 USD
CY2015 us-gaap Interest Expense Debt
InterestExpenseDebt
971000 USD
CY2014 us-gaap Interest Expense Debt
InterestExpenseDebt
1024000 USD
CY2015Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
2320000 USD
CY2015Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
2741000 USD
CY2015Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
2979000 USD
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-2649000 USD
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
-916000 USD
CY2014Q1 us-gaap Revenues
Revenues
42000 USD
CY2014Q2 us-gaap Revenues
Revenues
35000 USD
CY2014Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
151000 USD
CY2014Q3 us-gaap Revenues
Revenues
145000 USD
CY2014Q4 us-gaap Revenues
Revenues
529000 USD
CY2014Q1 us-gaap Costs And Expenses
CostsAndExpenses
3868000 USD
CY2014Q2 us-gaap Costs And Expenses
CostsAndExpenses
3307000 USD
CY2014Q3 us-gaap Costs And Expenses
CostsAndExpenses
2791000 USD
CY2014Q4 us-gaap Costs And Expenses
CostsAndExpenses
2984000 USD
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3826000 USD
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3272000 USD
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2646000 USD
CY2015 us-gaap Sale Leaseback Transaction Transaction Costs Financing Activities
SaleLeasebackTransactionTransactionCostsFinancingActivities
8000 USD
CY2015 us-gaap Sale Leaseback Transaction Net Proceeds Financing Activities
SaleLeasebackTransactionNetProceedsFinancingActivities
217000 USD
CY2014Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-2455000 USD
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-4088000 USD
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-3521000 USD
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-2904000 USD
CY2014Q4 us-gaap Net Income Loss
NetIncomeLoss
-2696000 USD
CY2014Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
146000 shares
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
1000 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
216000 shares
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
315000 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
384000 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
3.30
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.01
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
3.70
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
2.69
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.85
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.022 pure
CY2014Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
CY2014Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.30
CY2014Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.30
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
2050000 USD
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
2898000 USD
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.72
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.30
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.97 pure
CY2014 acur Share Based Compensation Share Based Payment Awards Cash Less Exercises
ShareBasedCompensationShareBasedPaymentAwardsCashLessExercises
5000 shares
CY2014 acur Share Based Compensation Share Based Payment Awards Cashless Exercises Withheld Minimum Payroll Taxes
ShareBasedCompensationShareBasedPaymentAwardsCashlessExercisesWithheldMinimumPayrollTaxes
3000 shares
CY2014 acur Taxes Withheld On Issuance Of Stock Based Awards
TaxesWithheldOnIssuanceOfStockBasedAwards
32000 USD
CY2014 acur Statutory Minimum Payroll Taxes
StatutoryMinimumPayrollTaxes
1000 USD
CY2015Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
1394000 USD
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
56622000 USD
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
55995000 USD
CY2014 acur Number Of Shares Issued On Cashless Exercises
NumberOfSharesIssuedOnCashlessExercises
2000 shares
CY2015 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1696000 USD
CY2014 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-4491000 USD
CY2015 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
41000 USD
CY2014 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
65000 USD
CY2015 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
0 USD
CY2014 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
30000 USD
CY2015 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
184000 USD
CY2014 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
262000 USD
CY2015 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
11000 USD
CY2014 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
2000 USD
CY2015 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1460000 USD
CY2014 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
4192000 USD
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
52772000 USD
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
51503000 USD
CY2014Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
1398000 USD
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
38000 USD
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
45000 USD
CY2015Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
368000 USD
CY2014Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.40
CY2014Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.35
CY2014Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.30
CY2014Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.30
CY2015 acur Milestone Revenue
MilestoneRevenue
2500000 USD
CY2014 acur Milestone Revenue
MilestoneRevenue
0 USD
CY2014 us-gaap Professional And Contract Services Expense
ProfessionalAndContractServicesExpense
100000 USD
CY2015Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
314000 USD
CY2015Q1 us-gaap Revenue Recognition Sales Returns Reserve For Sales Returns
RevenueRecognitionSalesReturnsReserveForSalesReturns
120000 USD
CY2015Q1 us-gaap Related Parties Amount In Cost Of Sales
RelatedPartiesAmountInCostOfSales
255000 USD
CY2013Q4 us-gaap Secured Debt
SecuredDebt
10000000 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
774000 USD
CY2015Q4 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
37000 USD
CY2014Q4 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
66000 USD
CY2015Q4 us-gaap Inventory Net
InventoryNet
276000 USD
CY2014Q4 us-gaap Inventory Net
InventoryNet
304000 USD
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
471000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2485000 USD
CY2014Q4 us-gaap Marketable Securities
MarketableSecurities
11322000 USD
CY2015Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
83000 USD
CY2014Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
76000 USD
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
417000 USD
CY2015Q4 us-gaap Deferred Tax Assets Gross Current
DeferredTaxAssetsGrossCurrent
0 USD
CY2014Q4 us-gaap Deferred Tax Assets Gross Current
DeferredTaxAssetsGrossCurrent
218000 USD
CY2015Q4 us-gaap Assets Current
AssetsCurrent
14135000 USD
CY2015Q4 us-gaap Other Assets
OtherAssets
175000 USD
CY2014Q4 us-gaap Other Assets
OtherAssets
0 USD
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
110000 USD
CY2015Q4 us-gaap Interest Payable Current
InterestPayableCurrent
0 USD
CY2014Q4 us-gaap Interest Payable Current
InterestPayableCurrent
70000 USD
CY2014Q4 acur Sales Returns Liability Current
SalesReturnsLiabilityCurrent
0 USD
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0 USD
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
353000 USD
CY2015Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2320000 USD
CY2014Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1758000 USD
CY2015Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
5430000 USD
CY2014Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
7799000 USD
CY2015Q4 us-gaap Marketable Securities
MarketableSecurities
10837000 USD
CY2014Q4 us-gaap Assets
Assets
16033000 USD
CY2015Q4 acur Longterm Portion Of Accrued Interest
LongtermPortionOfAccruedInterest
387000 USD
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-4001000 USD
CY2015 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
166000 USD
CY2015 us-gaap Interest Expense
InterestExpense
1157000 USD
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-4989000 USD
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-13209000 USD
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-4989000 USD
CY2015 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-52000 USD
CY2015 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-52000 USD
CY2014 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-32000 USD
CY2014 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13241000 USD
CY2014 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4000 USD
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
217000 USD
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
568000 USD
CY2014Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
26000 USD
CY2015Q4 acur Sales Returns Liability Current
SalesReturnsLiabilityCurrent
205000 USD
CY2014Q4 us-gaap Assets Current
AssetsCurrent
13231000 USD
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1013000 USD
CY2015Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1638000 USD
CY2015Q4 us-gaap Assets
Assets
16961000 USD
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-13209000 USD
CY2014 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-32000 USD
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5041000 USD
CY2015 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
CY2015 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
CY2015 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-988000 USD
CY2014 us-gaap Interest Expense
InterestExpense
1212000 USD
CY2014Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1845000 USD
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
564000 USD
CY2015Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
45000 USD
CY2014 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7940000 USD
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
957000 USD
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4582000 USD
CY2015 us-gaap Depreciation And Amortization
DepreciationAndAmortization
125000 USD
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-12199000 USD
CY2014 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
198000 USD
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2015 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10796000 shares
CY2015 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10796000 shares
CY2015 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
170000 USD
CY2015 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8994000 USD
CY2014Q4 acur Longterm Portion Of Accrued Interest
LongtermPortionOfAccruedInterest
190000 USD
CY2015Q4 us-gaap Liabilities
Liabilities
9061000 USD
CY2015 us-gaap Royalty Revenue
RoyaltyRevenue
5000 USD
CY2014 us-gaap Royalty Revenue
RoyaltyRevenue
4000 USD
CY2015 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
662000 USD
CY2014 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
247000 USD
CY2015 us-gaap License And Services Revenue
LicenseAndServicesRevenue
5250000 USD
CY2014 us-gaap License And Services Revenue
LicenseAndServicesRevenue
500000 USD
CY2015 us-gaap Revenues
Revenues
8587000 USD
CY2014 us-gaap Revenues
Revenues
751000 USD
CY2015 acur Cost Of Sales Excluding Inventory Write Down
CostOfSalesExcludingInventoryWriteDown
656000 USD
CY2014 acur Cost Of Sales Excluding Inventory Write Down
CostOfSalesExcludingInventoryWriteDown
227000 USD
CY2015 us-gaap Inventory Write Down
InventoryWriteDown
330000 USD
CY2014 us-gaap Inventory Write Down
InventoryWriteDown
201000 USD
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2608000 USD
CY2014 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.35
CY2014 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.35
CY2014 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1010000 USD
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2014 us-gaap Interest Paid
InterestPaid
765000 USD
CY2014 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
0 USD
CY2014 us-gaap Depreciation And Amortization
DepreciationAndAmortization
119000 USD
CY2015 acur Provision To Reduce Inventory To Net Realizable Value
ProvisionToReduceInventoryToNetRealizableValue
330000 USD
CY2014 acur Provision To Reduce Inventory To Net Realizable Value
ProvisionToReduceInventoryToNetRealizableValue
201000 USD
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
606000 USD
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
890000 USD
CY2015 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
186000 USD
CY2014 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
188000 USD
CY2015 acur Amortization Of Bond Premium In Marketable Securities
AmortizationOfBondPremiumInMarketableSecurities
127000 USD
CY2014 acur Amortization Of Bond Premium In Marketable Securities
AmortizationOfBondPremiumInMarketableSecurities
250000 USD
CY2015 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
207000 USD
CY2014 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
155000 USD
CY2015 us-gaap Increase Decrease In Accrued Investment Income Receivable
IncreaseDecreaseInAccruedInvestmentIncomeReceivable
-29000 USD
CY2014 us-gaap Increase Decrease In Accrued Investment Income Receivable
IncreaseDecreaseInAccruedInvestmentIncomeReceivable
-54000 USD
CY2015 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
302000 USD
CY2014 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
254000 USD
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-54000 USD
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-158000 USD
CY2015 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-218000 USD
CY2014 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
32000 USD
CY2015 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
175000 USD
CY2014 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-5000 USD
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-107000 USD
CY2014 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-57000 USD
CY2015 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4000 USD
CY2014 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
27000 USD
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-353000 USD
CY2014 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
66000 USD
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3688000 USD
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-11044000 USD
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
8000 USD
CY2015 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
127000 USD
CY2014 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
260000 USD
CY2015 us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
1000 USD
CY2014 us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
1000 USD
CY2015 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0 USD
CY2014 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
529000 USD
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
5291000 USD
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-520000 USD
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1711000 USD
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-11566000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12340000 USD
CY2015 us-gaap Interest Paid
InterestPaid
844000 USD
CY2015 acur Provision For Sales Returns
ProvisionForSalesReturns
267000 USD
CY2014 acur Provision For Sales Returns
ProvisionForSalesReturns
0 USD
CY2015 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
3522000 USD
CY2014 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
2203000 USD
CY2015 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
3830000 USD
CY2014 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
4336000 USD
CY2015 us-gaap Product Warranty Accrual Additions From Business Acquisition
ProductWarrantyAccrualAdditionsFromBusinessAcquisition
0 USD
CY2014 us-gaap Product Warranty Accrual Additions From Business Acquisition
ProductWarrantyAccrualAdditionsFromBusinessAcquisition
2000000 USD
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
214000 USD
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
135000 USD
CY2015 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
14000 USD
CY2014 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 USD
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
108000 USD
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-2000 USD
CY2015 acur Proceeds From Market Offering Of Shares
ProceedsFromMarketOfferingOfShares
225000 USD
CY2014 acur Proceeds From Market Offering Of Shares
ProceedsFromMarketOfferingOfShares
0 USD
CY2015 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
611000 USD
CY2014 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 USD
CY2015 us-gaap Repayments Of Debt
RepaymentsOfDebt
1960000 USD
CY2014 us-gaap Repayments Of Debt
RepaymentsOfDebt
0 USD
CY2015 acur Proceeds From Registered Direct Offering
ProceedsFromRegisteredDirectOffering
7636000 USD
CY2014 acur Proceeds From Registered Direct Offering
ProceedsFromRegisteredDirectOffering
0 USD
CY2015Q4 us-gaap Retail Related Inventory
RetailRelatedInventory
260000 USD
CY2015Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
3100000 USD
CY2014Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
3500000 USD
CY2015Q4 acur Available For Sale Securities Debt Maturities After One Through Three Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue
400000 USD
CY2014Q4 acur Available For Sale Securities Debt Maturities After One Through Three Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue
2800000 USD
CY2014Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
11300000 USD
CY2015Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
10800000 USD
CY2015Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
10900000 USD
CY2015 us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
0 USD
CY2015 us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
100000 USD
CY2014Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
11300000 USD
CY2014 us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
0 USD
CY2014 us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
0 USD
CY2015Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
0 USD
CY2014Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
260000 USD
CY2015Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
346000 USD
CY2014Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
44000 USD
CY2015Q4 us-gaap Inventory Gross
InventoryGross
346000 USD
CY2014Q4 us-gaap Inventory Gross
InventoryGross
304000 USD
CY2015Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
70000 USD
CY2015 us-gaap Depreciation
Depreciation
100000 USD
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
101000 USD
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
94000 USD
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
171000 USD
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
253000 USD
CY2015Q4 acur Other Accrued Taxes Current
OtherAccruedTaxesCurrent
6000 USD
CY2014Q4 acur Other Accrued Taxes Current
OtherAccruedTaxesCurrent
13000 USD
CY2015Q4 us-gaap Accrual For Taxes Other Than Income Taxes Current
AccrualForTaxesOtherThanIncomeTaxesCurrent
15000 USD
CY2014Q4 us-gaap Accrual For Taxes Other Than Income Taxes Current
AccrualForTaxesOtherThanIncomeTaxesCurrent
15000 USD
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
64000 USD
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
110000 USD
CY2013Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
10000000 USD
CY2013Q4 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.0835 pure
CY2013Q4 acur Debt Default Long Term Debt Percentage
DebtDefaultLongTermDebtPercentage
0.1335 pure
CY2015 us-gaap Debt Instrument Periodic Payment
DebtInstrumentPeriodicPayment
260000 USD
CY2015 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2018-12-01
CY2015Q1 acur Additions To Debt Instrument Unamortized Discount
AdditionsToDebtInstrumentUnamortizedDiscount
33000 USD
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1741000 USD
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1794000 USD
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.024 pure
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.92 pure
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2015Q4 us-gaap Related Parties Amount In Cost Of Sales
RelatedPartiesAmountInCostOfSales
255000 USD
CY2015 us-gaap Revenue Recognition Sales Returns Reserve For Sales Returns
RevenueRecognitionSalesReturnsReserveForSalesReturns
205000 USD
CY2015 us-gaap Professional And Contract Services Expense
ProfessionalAndContractServicesExpense
200000 USD
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2754000 USD
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2751000 USD
CY2015 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
7033000 USD
CY2014 us-gaap Deferred Revenue Revenue Recognized
DeferredRevenueRevenueRecognized
353000 USD
CY2015Q4 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
314000 USD
CY2015Q4 us-gaap Revenue Recognition Sales Returns Reserve For Sales Returns
RevenueRecognitionSalesReturnsReserveForSalesReturns
120000 USD
CY2014Q4 us-gaap New Accounting Pronouncement Or Change In Accounting Principle Cumulative Effect Of Change On Equity Or Net Assets1
NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1
162000 USD
CY2015 acur Agreement Termination Notice Description
AgreementTerminationNoticeDescription
Egalet may terminate the Egalet Agreement for convenience on 120 days prior written notice, which termination may not occur prior to the second anniversary of Egalets launch of Oxaydo. Termination does not affect a partys rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the Egalet Agreement provides for the transition of development and marketing of Oxaydo from Egalet to us, including the conveyance by Egalet to us of the trademarks and all regulatory filings and approvals relating to Oxaydo, and for Egalets supply of Oxaydo for a transition period.
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
6000 USD
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0 USD
CY2015Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
711000 USD
acur Placement Agency Reimbursed For Expenses
PlacementAgencyReimbursedForExpenses
496000 USD

Files In Submission

Name View Source Status
0001144204-16-085018-index-headers.html Edgar Link pending
0001144204-16-085018-index.html Edgar Link pending
0001144204-16-085018.txt Edgar Link pending
0001144204-16-085018-xbrl.zip Edgar Link pending
acur-20151231.xml Edgar Link completed
acur-20151231.xsd Edgar Link pending
acur-20151231_cal.xml Edgar Link unprocessable
acur-20151231_def.xml Edgar Link unprocessable
acur-20151231_lab.xml Edgar Link unprocessable
acur-20151231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v431942_10k.htm Edgar Link pending
v431942_ex23-1.htm Edgar Link pending
v431942_ex31-1.htm Edgar Link pending
v431942_ex31-2.htm Edgar Link pending
v431942_ex32.htm Edgar Link pending